会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF
    • 新生受体TREM(在MYELOID细胞上表达的触发受体)及其用途
    • US20100305306A1
    • 2010-12-02
    • US12687038
    • 2010-01-13
    • Marco COLONNAAxel Bouchon
    • Marco COLONNAAxel Bouchon
    • C07K16/00
    • C07K14/70503
    • Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
    • 提供了称为TREM(在骨髓细胞上表达的触发受体)的人类骨髓细胞上表达的Ig超家族的新型活化受体。 具体地说,公开了TREMs,TREM-1和TREM-2的两(2)个成员。 TREM-1是一种在血液嗜中性粒细胞和单核细胞亚群上有选择性表达而不是淋巴细胞和其他细胞类型的跨膜糖蛋白,并被细菌和真菌产品上调。 还提供了TREM-1在各种炎性疾病的治疗和诊断中的应用。 TREM-2也是在肥大细胞和外周树突状细胞(DC)上选择性表达但不在粒细胞或单核细胞上表达的跨膜糖蛋白。 通过TREM-2的DC刺激导致DC成熟和对细胞凋亡的抗性,并且诱导CCR7的强烈上调和随后对巨噬细胞炎症蛋白质3-&bgr的趋化性。 TREM-2可用于调节各种免疫疾病中的宿主免疫应答,包括自身免疫性疾病和过敏性疾病。
    • 6. 发明申请
    • 1,3 Aclyated 24-keto-vitamin d3 compounds and methods of use thereof
    • 1,3 Acetated 24-酮维生素D 3化合物及其使用方法
    • US20070032461A1
    • 2007-02-08
    • US10554769
    • 2004-04-30
    • Luciano AdoriniGiuseppe PennaMilan UskokovicHubert Maehr
    • Luciano AdoriniGiuseppe PennaMilan UskokovicHubert Maehr
    • A61K31/59C07C401/00
    • C07C401/00
    • The invention provides 1,3 acylated, 24-keto vitamin D3 compounds of formula I: wherein: X1 and X1 are each independently H2 or ═CH2, provided X1 and X1 are not both ═CH2; R1 and R2 are each independently, hydroxyl, OC(O)C1-C4 alkyl, OC(O)hydroxyalkyl, OC(O)haloalkyl, provided that R1 and R2 are not both hydroxyl; R3 and R4 are each independently hydrogen, C1-C4 alkyl, hydroxyalkyl, or haloalkyl, or R3 and R4 taken together with C20 form C3-C6 cylcoalkyl; and R5 and R6 are each independently C1-C4 alkyl, hydroxyalkyl, or haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof. Methods for using the compounds to treat vitamin D3 associated states, and phar,aceutical compositions containing the compounds are also disclosed.
    • 本发明提供1,3-酰化的24-酮维生素D 3 O 3式III化合物:其中:X 1和X 1各自独立地为 H 2或-CH 2,条件是X 1和X 1不同时为-CH 2 R 1和R 2各自独立地为羟基,OC(O)C 1 -C 4烷基, OC(O)羟基烷基,OC(O)卤代烷基,条件是R 1和R 2不都是羟基; R 3和R 4各自独立地为氢,C 1 -C 4烷基,羟基烷基或卤代烷基,或R 3和R 4 < / SUB>与C 20 - C 3 -C 3 -C 6 - 环烷基一起取代; 和R 5和R 6各自独立地为C 1 -C 4烷基,羟基烷基或卤代烷基; 和其药学上可接受的酯,盐和前药。 还公开了使用该化合物来治疗维生素D 3 3相关状态的方法,以及含有该化合物的药用组合物。